Search

Search Results
Results 4581 - 4590 of 4639 for multiple sclerosis
  • APX-Paracetamol/Codeine
    Drug - 4 Apr 2025
    Consumer Medicine Information (CMI) about APX-Paracetamol/Codeine intended for persons living in Australia.
  • Humira
    Drug - 11 Mar 2025
    Consumer Medicine Information (CMI) about Humira intended for persons living in Australia.
  • Top Sessions: 15th Clinical Biomarkers & CDx Summit Europe
    White Paper - 6 Mar 2025
    Discover the top sessions at Hanson Wade's 15th Clinical Biomarkers & CDx Summit Europe.
  • Top challenges: 15th Clinical Biomarkers & CDx Summit Europe
    White Paper - 6 Mar 2025
    Discover the top challenges tackled at Hanson Wade's 15th Clinical Biomarkers & CDx Summit Europe
  • Simponi
    Drug - 4 Mar 2025
    Consumer Medicine Information (CMI) about Simponi intended for persons living in Australia.
  • Expanding new trends and technologies in ADC therapeutics
    White Paper - 18 Feb 2025
    Explore the latest advancements and innovative technologies in ADC therapeutics, driving new possibilities for targeted drug delivery.
  • Entyvio Pen
    Drug - 24 Jan 2025
    Consumer Medicine Information (CMI) about Entyvio Pen intended for persons living in Australia.
  • Entyvio IV
    Drug - 24 Jan 2025
    Consumer Medicine Information (CMI) about Entyvio IV intended for persons living in Australia.
  • Lioresal Tablets
    Drug - 23 Jan 2025
    Consumer Medicine Information (CMI) about Lioresal Tablets intended for persons living in Australia.
  • Juluca
    Drug - 13 Jan 2025
    Consumer Medicine Information (CMI) about Juluca intended for persons living in Australia.

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback